Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Sensitive Test Developed for Sleeping Sickness

By LabMedica International staff writers
Posted on 05 Jun 2012
Proteins imitating typical parts of the sleeping sickness parasite can be used in more efficient diagnostic tests, without the need for culturing dangerous parasites. More...


In the regions where Trypanosoma brucei gambiense, the causative agent of sleeping sickness is found, medical workers for decades already use a rapid diagnostic test, to screen millions of people each year on the presence of antibodies in their blood.

A scientist at the Antwerp Institute of Tropical Medicine (Belgium) has developed a new and better test by trying to synthesize artificial targets. These 'mimotopes' mimic only a part of the original target protein, but still are sufficient to react with the patient's antibodies. The investigator produced mimotopes that are reliable and react with infected patients' serum. These mimotopes now can be the base for a new generation of rapid diagnostic tests for sleeping sickness.

In the original tests the antibodies are demonstrated by presenting them targets they will also recognize and attack on real trypanosomes such as the variable surface glycoprotein that cover the parasite as a mantle. When antibody and target react, the test is positive and is made visible by for instance a color change or a clotting. Today those targets are obtained from living parasites that are raised in laboratory animals, and are a constant danger for the laboratory technicians.

In an early stage, the disease is easy to treat, but once the brain is invaded, the treatment becomes more complex and physicians must use medicines with dangerous, even deadly, side effects. Therefore, it is important to detect the infection early. Patients become disoriented, their sleeping pattern disintegrates, and they get motor and mental problems. This inevitably leads to coma and death. According to the World Health Organization (WHO; Geneva, Switzerland) estimates, sleeping sickness claims 10,000 to 20,000 lives each year. In recent years, the number of cases has come down substantially, thanks to campaigns against the disease, so error margins that were acceptable in the old days, because the tests still saved so many lives, now become inadmissible.

Related Links:

Antwerp Institute of Tropical Medicine
World Health Organization



Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Homocysteine Quality Control
Liquichek Homocysteine Control
Capillary Blood Collection Tube
IMPROMINI M3
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.